Hiddo J. L. Heerspink
Department of Clinical Pharmacy and Pharmacology University Medical Centre Groningen
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hiddo J. L. Heerspink as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04492722 · A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney DiseaseAstraZeneca · terminated · Chronic Kidney Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:58 UTC. The ranking covers the 200 most relevant of 203 PubMed records, and a shared surname and initials can bring in a namesake. All 203 on PubMed
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.N Engl J Med · 20194,815 citationsRCR 240.8
- Dapagliflozin in Patients with Chronic Kidney Disease.N Engl J Med · 20204,442 citationsRCR 255.6
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.Lancet Diabetes Endocrinol · 2019545 citationsRCR 25.6
- 543 citationsRCR 25.1
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.Lancet Diabetes Endocrinol · 2021433 citationsRCR 28.3
- Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).Eur J Heart Fail · 2020364 citationsRCR 17.7
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.Kidney Int · 2021360 citationsRCR 24.4
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.J Am Soc Nephrol · 2017279 citationsRCR 11.5
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.N Engl J Med · 2025276 citationsRCR 81.0
- 267 citationsRCR 30.3